Cargando…
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
Aggressive large B-cell lymphomas represent a diverse population of diseases that are typically treated with anti-CD20 based immunochemotherapy. While this treatment is effective for a large proportion of patients, those that become refractory to induction therapy or experience disease relapse suffe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990602/ https://www.ncbi.nlm.nih.gov/pubmed/32064069 http://dx.doi.org/10.1177/2040620720902899 |